{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:29Z","timestamp":1792788029224,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2020SK1014-3"],"award-info":[{"award-number":["2020SK1014-3"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2020SK2114"],"award-info":[{"award-number":["2020SK2114"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Provincial Key Laboratory of Emergency Medicine for Children","award":["2018TP1028"],"award-info":[{"award-number":["2018TP1028"]}]},{"DOI":"10.13039\/501100010909","name":"Young Scientists Fund","doi-asserted-by":"publisher","award":["82102285"],"award-info":[{"award-number":["82102285"]}],"id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2021JJ40270"],"award-info":[{"award-number":["2021JJ40270"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Project of Hunan Provincial Health Commission","award":["202112050360"],"award-info":[{"award-number":["202112050360"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder. How to stratify high risk patients is one of the current challenges for the treatment of HLH. HLH patients usually fulfill multiple but not all eight diagnostic criteria. Different combinations of the fulfilled criteria may naturally cluster into previously undescribed subsets or phenotypes that may have different pathophysiology and demonstrate different risks for a poor outcome. The objectives of this study were to identify HLH subgroups according to the fulfillment of diagnostic criteria and evaluate the risk of multiple organ dysfunction syndrome (MODS) and 30-day mortality for subgroups. We retrospectively collect medical records of patients with discharge diagnosis of HLH between June 2015 and October 2018 from a tertiary children\u2019s hospital in China. Latent class analysis was used to identify class defining variables from HLH diagnostic items, and subgroups were defined according to different combinations of the class defining variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Triglyceride and fibrinogen were identified as the class defining variables. When evaluated in combinations, patients with hypertriglyceridemia and normal fibrinogen levels during hospitalization had the lowest risks for MODS (27.8%, OR\u2009=\u20091) and 30-day mortality (18.8%, OR\u2009=\u20091), and patients with normal triglyceride and hypofibrinogenemia had the highest risks for MODS (86.2%, OR\u2009=\u200916.24,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0002) and 30-day mortality (57.1%, OR\u2009=\u20095.78,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0187). The fulfillment status of hypertriglyceridemia and hypofibrinogenemia within 72\u00a0h of hospital admission was also associated with the risk of adverse outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The fulfillment status of hypertriglyceridemia and hypofibrinogenemia were associated with the risks of MODS and 30-day mortality among pediatric HLH patients. Further studies are needed to validate this association and investigate its clinical utility in the severity evaluation for HLH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-022-02315-8","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T07:07:11Z","timestamp":1649660831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Fulfillment status of hypertriglyceridemia and hypofibrinogenemia in children with hemophagocytic lymphohistiocytosis and risks of multiple organ dysfunction syndrome and early mortality"],"prefix":"10.1186","volume":"17","author":[{"given":"Xun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaotian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mincui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenya","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-5623","authenticated-orcid":false,"given":"Xiulan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"issue":"2","key":"2315_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood Cancer. 2007;48(2):124\u201331. https:\/\/doi.org\/10.1002\/pbc.21039.","journal-title":"Pediatric Blood Cancer"},{"issue":"15","key":"2315_CR2","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","volume":"118","author":"MB Jordan","year":"2011","unstructured":"Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041\u201352. https:\/\/doi.org\/10.1182\/blood-2011-03-278127.","journal-title":"Blood"},{"issue":"3","key":"2315_CR3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaip.2018.11.050","volume":"7","author":"KA Risma","year":"2019","unstructured":"Risma KA, Marsh RA. Hemophagocytic lymphohistiocytosis: clinical presentations and diagnosis. J Allergy Clin Immunol Pract. 2019;7(3):824\u201332. https:\/\/doi.org\/10.1016\/j.jaip.2018.11.050.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2315_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bjh.14144","volume":"174","author":"E Brisse","year":"2016","unstructured":"Brisse E, Matthys P, Wouters CH. Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br J Haematol. 2016;174(2):175\u201387. https:\/\/doi.org\/10.1111\/bjh.14144.","journal-title":"Br J Haematol"},{"issue":"2","key":"2315_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/bjh.14147","volume":"174","author":"E Brisse","year":"2016","unstructured":"Brisse E, Wouters CH, Matthys P. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities. Br J Haematol. 2016;174(2):203\u201317. https:\/\/doi.org\/10.1111\/bjh.14147.","journal-title":"Br J Haematol"},{"key":"2315_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01390-z","author":"J Zhang","year":"2020","unstructured":"Zhang J, Sun Y, Shi X, Zhang R, Wang Y, Xiao J, et al. Genotype characteristics and immunological indicator evaluation of 311 hemophagocytic lymphohistiocytosis cases in China. Orphanet J Rare Dis. 2020. https:\/\/doi.org\/10.1186\/s13023-020-01390-z.","journal-title":"Orphanet J Rare Dis"},{"key":"2315_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cyto.2017.03.013","volume":"97","author":"ZB Luo","year":"2017","unstructured":"Luo ZB, Chen YY, Xu XJ, Zhao N, Tang YM. Prognostic factors of early death in children with hemophagocytic lymphohistiocytosis. Cytokine. 2017;97:80\u20135. https:\/\/doi.org\/10.1016\/j.cyto.2017.03.013.","journal-title":"Cytokine"},{"issue":"3","key":"2315_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3109\/08880018.2013.858198","volume":"31","author":"AT Dao","year":"2014","unstructured":"Dao AT, Luong VT, Nguyen TT, Huynh QT, Phan TT, Lam MT, et al. Risk factors for early fatal outcomes among children with hemophagocytic lymphohistiocytosis (HLH): a single-institution case-series in Vietnam. Pediatr Hematol Oncol. 2014;31(3):271\u201381. https:\/\/doi.org\/10.3109\/08880018.2013.858198.","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"2315_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1651-2227.2011.02501.x","volume":"101","author":"H Trottestam","year":"2012","unstructured":"Trottestam H, Berglof E, Horne A, Onelov E, Beutel K, Lehmberg K, et al. Risk factors for early death in children with haemophagocytic lymphohistiocytosis. Acta Paediatr. 2012;101(3):313\u20138. https:\/\/doi.org\/10.1111\/j.1651-2227.2011.02501.x.","journal-title":"Acta Paediatr"},{"issue":"1","key":"2315_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13023-020-01515-4","volume":"15","author":"X Li","year":"2020","unstructured":"Li X, Yan H, Zhang X, Huang J, Xiang S-T, Yao Z, et al. Clinical profiles and risk factors of 7-day and 30-day mortality among 160 pediatric patients with hemophagocytic lymphohistiocytosis. Orphanet J Rare Dis. 2020;15(1):229. https:\/\/doi.org\/10.1186\/s13023-020-01515-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2315_CR11","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jama.2020.2278","volume":"324","author":"M Mori","year":"2020","unstructured":"Mori M, Krumholz HM, Allore HG. Using latent class analysis to identify hidden clinical phenotypes. JAMA. 2020;324(7):700\u20131. https:\/\/doi.org\/10.1001\/jama.2020.2278.","journal-title":"JAMA"},{"key":"2315_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.692849","author":"X Li","year":"2021","unstructured":"Li X, Yan H, Xiao Z, Zhang X, Huang J, Xiang S-T, et al. Diagnostic time lag of pediatric haemophagocytic lymphohistiocytosis and patient characteristics: a retrospective cohort study. Front Pediatr. 2021. https:\/\/doi.org\/10.3389\/fped.2021.692849.","journal-title":"Front Pediatr"},{"key":"2315_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/JBM.S46255","volume":"5","author":"MR George","year":"2014","unstructured":"George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014;5:69\u201386. https:\/\/doi.org\/10.2147\/JBM.S46255.","journal-title":"J Blood Med"},{"issue":"9","key":"2315_CR14","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00277-016-2727-6","volume":"95","author":"Q Bin","year":"2016","unstructured":"Bin Q, Gao JH, Luo JM. Prognostic factors of early outcome in pediatric hemophagocytic lymphohistiocytosis: an analysis of 116 cases. Ann Hematol. 2016;95(9):1411\u20138. https:\/\/doi.org\/10.1007\/s00277-016-2727-6.","journal-title":"Ann Hematol"},{"issue":"6","key":"2315_CR15","first-page":"421","volume":"6","author":"HW Harris","year":"2000","unstructured":"Harris HW, Gosnell JE, Kumwenda ZL. The lipemia of sepsis: triglyceride-rich lipoproteins as agents of innate immunity. J Endotoxin Res. 2000;6(6):421\u201330.","journal-title":"J Endotoxin Res"},{"issue":"Suppl 7","key":"2315_CR16","doi-asserted-by":"publisher","first-page":"S498","DOI":"10.1086\/432005","volume":"41","author":"AM Barcia","year":"2005","unstructured":"Barcia AM, Harris HW. Triglyceride-rich lipoproteins as agents of innate immunity. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005;41(Suppl 7):S498-503. https:\/\/doi.org\/10.1086\/432005.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"2","key":"2315_CR17","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/cc11256","volume":"16","author":"D Demirkol","year":"2012","unstructured":"Demirkol D, Yildizdas D, Bayrakci B, Karapinar B, Kendirli T, Koroglu TF, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction syndrome\/macrophage activation syndrome: what is the treatment? Crit Care. 2012;16(2):R52. https:\/\/doi.org\/10.1186\/cc11256.","journal-title":"Crit Care"},{"issue":"4","key":"2315_CR18","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1378\/chest.11-0619","volume":"140","author":"RA Raschke","year":"2011","unstructured":"Raschke RA, Garcia-Orr R. Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults. Chest. 2011;140(4):933\u20138. https:\/\/doi.org\/10.1378\/chest.11-0619.","journal-title":"Chest"},{"key":"2315_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13023-015-0224-y","volume":"10","author":"F Li","year":"2015","unstructured":"Li F, Yang Y, Jin F, Dehoedt C, Rao J, Zhou Y, et al. Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China. Orphanet J Rare Dis. 2015;10:20. https:\/\/doi.org\/10.1186\/s13023-015-0224-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"20","key":"2315_CR20","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","volume":"321","author":"CW Seymour","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003\u201317. https:\/\/doi.org\/10.1001\/jama.2019.5791.","journal-title":"JAMA"},{"issue":"11","key":"2315_CR21","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00134-018-5378-3","volume":"44","author":"P Sinha","year":"2018","unstructured":"Sinha P, Delucchi KL, Thompson BT, McAuley DF, Matthay MA, Calfee CS, et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 2018;44(11):1859\u201369. https:\/\/doi.org\/10.1007\/s00134-018-5378-3.","journal-title":"Intensive Care Med"},{"issue":"11","key":"2315_CR22","doi-asserted-by":"publisher","first-page":"e27929","DOI":"10.1002\/pbc.27929","volume":"66","author":"MB Jordan","year":"2019","unstructured":"Jordan MB, Allen CE, Greenberg J, Henry M, Hermiston ML, Kumar A, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66(11):e27929. https:\/\/doi.org\/10.1002\/pbc.27929.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2315_CR23","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","volume":"6","author":"S Ehl","year":"2018","unstructured":"Ehl S, Astigarraga I, von Bahr GT, Hines M, Horne A, Ishii E, et al. Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract. 2018;6(5):1508\u201317. https:\/\/doi.org\/10.1016\/j.jaip.2018.05.031.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2315_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","volume":"39","author":"RP Dellinger","year":"2012","unstructured":"Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2012;39(2):165\u2013228. https:\/\/doi.org\/10.1007\/s00134-012-2769-8.","journal-title":"Intensive Care Med"},{"issue":"1","key":"2315_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/01.pcc.0000149131.72248.e6","volume":"6","author":"B Goldstein","year":"2005","unstructured":"Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2005;6(1):2\u20138. https:\/\/doi.org\/10.1097\/01.pcc.0000149131.72248.e6.","journal-title":"Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc"},{"issue":"27","key":"2315_CR26","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128.","journal-title":"Eur Heart J"},{"issue":"10","key":"2315_CR27","first-page":"986","volume":"77","author":"RK Aneja","year":"2011","unstructured":"Aneja RK, Carcillo JA. Differences between adult and pediatric septic shock. Minerva Anestesiol. 2011;77(10):986\u201392.","journal-title":"Minerva Anestesiol"},{"issue":"5","key":"2315_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.ajkd.2013.02.349","volume":"61","author":"PM Palevsky","year":"2013","unstructured":"Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis Off J Natl Kidney Found. 2013;61(5):649\u201372. https:\/\/doi.org\/10.1053\/j.ajkd.2013.02.349.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"23","key":"2315_CR29","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1001\/jama.2012.5669","volume":"307","author":"VM Ranieri","year":"2012","unstructured":"Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526\u201333. https:\/\/doi.org\/10.1001\/jama.2012.5669.","journal-title":"JAMA"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02315-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02315-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02315-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T07:16:29Z","timestamp":1649661389000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02315-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2315"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02315-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"26 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Medical Ethics Committee of the Hunan Children's Hospital (HCHLL-2019-40). Informed consent was waved because of the retrospective design. The authors had no access to information that could identify individual participants during and after data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}